Salvianolic Acids for Injection (SAFI) suppresses inflammatory responses in activated microglia to attenuate brain damage in focal cerebral ischemia

Pengwei Zhuang, Yanjun Jean Wan, Shihan Geng, Ying He, Aichun Ju

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Inflammatory reactions induced by microglia in the brain play crucial roles in ischemia/reperfusion (I/R) cerebral injuries. Microglia activation has been shown to be closely related to TLR4/NF-κB signal pathways. Salvianolic acids for injection (SAFI) have been used in clinical practice to treat ischemic stroke with reported neuroprotective effects; however, the underlying mechanisms are still uncertain. Objective and Methods First, we studied the effect of SAFI on inflammatory responses in LPS-stimulated BV-2 microglia. Then, to discover whether the beneficial in vitro effects of SAFI lead to in vivo therapeutic effects, an MCAO (Middle cerebral artery occlusion) rat model was further employed to elucidate the probable mechanism of SAFI in treating ischemic stroke. Rats in the SAFI group were given SAFI (23 or 46 mg/kg) before I/R injury. Results The results showed that SAFI treatment significantly decreased neuroinflammation and the infarction volume compared with the vehicle group. Activation of microglia cells was reduced, and TLR4/NF-κB signals, which were markedly inhibited by SAFI treatment in ischemic hemisphere, were accompanied by reduced expression and release of cytokines IL-1β and IL-6. Conclusion This study provides evidence that SAFI effectively protects the brain after cerebral ischemia, which may be caused by attenuating inflammation in microglia.

Original languageEnglish (US)
Pages (from-to)194-204
Number of pages11
JournalJournal of Ethnopharmacology
Volume198
DOIs
StatePublished - Feb 23 2017

Fingerprint

Microglia
Brain Ischemia
Injections
Brain
Reperfusion Injury
Stroke
salvianolic acid
Middle Cerebral Artery Infarction
Neuroprotective Agents
Therapeutic Uses
Interleukin-1
Infarction
Interleukin-6
Signal Transduction
Cytokines
Inflammation
Therapeutics

Keywords

  • Inflammatory reaction
  • Ischemia/Reperfusion cerebral injury
  • Microglia
  • Salvianolic Acids for Injection
  • TLR4/NF-κB signals

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Salvianolic Acids for Injection (SAFI) suppresses inflammatory responses in activated microglia to attenuate brain damage in focal cerebral ischemia. / Zhuang, Pengwei; Wan, Yanjun Jean; Geng, Shihan; He, Ying; Ju, Aichun.

In: Journal of Ethnopharmacology, Vol. 198, 23.02.2017, p. 194-204.

Research output: Contribution to journalArticle

@article{33b6e59623d342ae93a0858665141296,
title = "Salvianolic Acids for Injection (SAFI) suppresses inflammatory responses in activated microglia to attenuate brain damage in focal cerebral ischemia",
abstract = "Background Inflammatory reactions induced by microglia in the brain play crucial roles in ischemia/reperfusion (I/R) cerebral injuries. Microglia activation has been shown to be closely related to TLR4/NF-κB signal pathways. Salvianolic acids for injection (SAFI) have been used in clinical practice to treat ischemic stroke with reported neuroprotective effects; however, the underlying mechanisms are still uncertain. Objective and Methods First, we studied the effect of SAFI on inflammatory responses in LPS-stimulated BV-2 microglia. Then, to discover whether the beneficial in vitro effects of SAFI lead to in vivo therapeutic effects, an MCAO (Middle cerebral artery occlusion) rat model was further employed to elucidate the probable mechanism of SAFI in treating ischemic stroke. Rats in the SAFI group were given SAFI (23 or 46 mg/kg) before I/R injury. Results The results showed that SAFI treatment significantly decreased neuroinflammation and the infarction volume compared with the vehicle group. Activation of microglia cells was reduced, and TLR4/NF-κB signals, which were markedly inhibited by SAFI treatment in ischemic hemisphere, were accompanied by reduced expression and release of cytokines IL-1β and IL-6. Conclusion This study provides evidence that SAFI effectively protects the brain after cerebral ischemia, which may be caused by attenuating inflammation in microglia.",
keywords = "Inflammatory reaction, Ischemia/Reperfusion cerebral injury, Microglia, Salvianolic Acids for Injection, TLR4/NF-κB signals",
author = "Pengwei Zhuang and Wan, {Yanjun Jean} and Shihan Geng and Ying He and Aichun Ju",
year = "2017",
month = "2",
day = "23",
doi = "10.1016/j.jep.2016.11.052",
language = "English (US)",
volume = "198",
pages = "194--204",
journal = "Journal of Ethnopharmacology",
issn = "0378-8741",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Salvianolic Acids for Injection (SAFI) suppresses inflammatory responses in activated microglia to attenuate brain damage in focal cerebral ischemia

AU - Zhuang, Pengwei

AU - Wan, Yanjun Jean

AU - Geng, Shihan

AU - He, Ying

AU - Ju, Aichun

PY - 2017/2/23

Y1 - 2017/2/23

N2 - Background Inflammatory reactions induced by microglia in the brain play crucial roles in ischemia/reperfusion (I/R) cerebral injuries. Microglia activation has been shown to be closely related to TLR4/NF-κB signal pathways. Salvianolic acids for injection (SAFI) have been used in clinical practice to treat ischemic stroke with reported neuroprotective effects; however, the underlying mechanisms are still uncertain. Objective and Methods First, we studied the effect of SAFI on inflammatory responses in LPS-stimulated BV-2 microglia. Then, to discover whether the beneficial in vitro effects of SAFI lead to in vivo therapeutic effects, an MCAO (Middle cerebral artery occlusion) rat model was further employed to elucidate the probable mechanism of SAFI in treating ischemic stroke. Rats in the SAFI group were given SAFI (23 or 46 mg/kg) before I/R injury. Results The results showed that SAFI treatment significantly decreased neuroinflammation and the infarction volume compared with the vehicle group. Activation of microglia cells was reduced, and TLR4/NF-κB signals, which were markedly inhibited by SAFI treatment in ischemic hemisphere, were accompanied by reduced expression and release of cytokines IL-1β and IL-6. Conclusion This study provides evidence that SAFI effectively protects the brain after cerebral ischemia, which may be caused by attenuating inflammation in microglia.

AB - Background Inflammatory reactions induced by microglia in the brain play crucial roles in ischemia/reperfusion (I/R) cerebral injuries. Microglia activation has been shown to be closely related to TLR4/NF-κB signal pathways. Salvianolic acids for injection (SAFI) have been used in clinical practice to treat ischemic stroke with reported neuroprotective effects; however, the underlying mechanisms are still uncertain. Objective and Methods First, we studied the effect of SAFI on inflammatory responses in LPS-stimulated BV-2 microglia. Then, to discover whether the beneficial in vitro effects of SAFI lead to in vivo therapeutic effects, an MCAO (Middle cerebral artery occlusion) rat model was further employed to elucidate the probable mechanism of SAFI in treating ischemic stroke. Rats in the SAFI group were given SAFI (23 or 46 mg/kg) before I/R injury. Results The results showed that SAFI treatment significantly decreased neuroinflammation and the infarction volume compared with the vehicle group. Activation of microglia cells was reduced, and TLR4/NF-κB signals, which were markedly inhibited by SAFI treatment in ischemic hemisphere, were accompanied by reduced expression and release of cytokines IL-1β and IL-6. Conclusion This study provides evidence that SAFI effectively protects the brain after cerebral ischemia, which may be caused by attenuating inflammation in microglia.

KW - Inflammatory reaction

KW - Ischemia/Reperfusion cerebral injury

KW - Microglia

KW - Salvianolic Acids for Injection

KW - TLR4/NF-κB signals

UR - http://www.scopus.com/inward/record.url?scp=85009513520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009513520&partnerID=8YFLogxK

U2 - 10.1016/j.jep.2016.11.052

DO - 10.1016/j.jep.2016.11.052

M3 - Article

C2 - 28087473

AN - SCOPUS:85009513520

VL - 198

SP - 194

EP - 204

JO - Journal of Ethnopharmacology

JF - Journal of Ethnopharmacology

SN - 0378-8741

ER -